Publications by authors named "Amy Bock"

Claim this Profile
U
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.
Jonathan Kay, Amy E Bock, Muhammad Rehman, Wuyan Zhang, Min Zhang

RMD Open· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
Roy M Fleischmann, Amy E Bock, Wuyan Zhang, Charles M Godfrey, Ivana Vranic

Rheumatol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects.
Donna S Cox, Daniel F Alvarez, Amy E Bock, Carol L Cronenberger

Clin Pharmacol Drug Dev· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, Carol Cronenberger, Ivana Vranic

Arthritis Res Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, Carol Cronenberger, Ivana Vranic

RMD Open· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
Roy M Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y Hua, Amy E Bock

Arthritis Res Ther· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development by a Large Integrated Health Care System of an Objective Methodology for Evaluation of Medical Oncology Service Sites.
Marija Bjegovich-Weidman, Jill Kahabka, Amy Bock, Jacob Frick, Helga Kowalski

J Oncol Pract· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis